Does Rallies show live market data for ADIL?

Rallies combines live market context with ticker research for ADIL, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

ADIL (Adial Pharmaceuticals, Inc) Stock Analysis

Adial Pharmaceuticals, Inc (ADIL) is a publicly traded Healthcare sector company. As of May 21, 2026, ADIL trades at $2.36 with a market cap of $3.45M and a P/E ratio of -0.19. ADIL moved +14.08% today. Year to date, ADIL is -63.15%; over the trailing twelve months it is -87.06%. Its 52-week range spans $1.31 to $32.50. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ADIL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest ADIL stock research?

Adial Pharmaceuticals, Inc (ADIL) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ADIL moved +14.08% today. Analyst consensus is buy.

ADIL Key Metrics

Key financial metrics for ADIL
Metric	Value
Price	$2.36
Market Cap	$3.45M
P/E Ratio	-0.19
EPS	$-11.93
Dividend Yield	0.00%
52-Week High	$32.50
52-Week Low	$1.31
Volume	318.21K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-7.98M
Gross Margin	0.00%

Latest ADIL News

FDA Flexibility Could Cut AD04 Costs; Company Holds $4.6M, Eyes Europe — May 11, 2026
Adial Pharmaceuticals Files U.S. Patent for AD04, Potential Protection Through 2045 — Apr 29, 2026
Adial Completes AD04 Demonstration Batch Meeting All Spec Targets for Phase 3 — Apr 22, 2026
Bill Expands AUD Research for Veterans, Elevates Adial’s AD04 Potential — Mar 24, 2026
Adial Ends 2025 with $5.9M Cash, R&D Down 19%, AD04 Phase 3 Ready — Mar 6, 2026

Recent ADIL Insider Trades

Schuyler Kevin bought 700 (~$1.92K) on Sep 29, 2023.
Newman James W. Jr. bought 10.00K (~$26.60K) on Dec 30, 2021.
Newman James W. Jr. bought 5.00K (~$13.60K) on Dec 30, 2021.

ADIL Analyst Consensus

1 analysts cover ADIL: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about ADIL

What can I research for ADIL on Rallies?: Adial Pharmaceuticals, Inc (ADIL) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ADIL moved +14.08% today. Analyst consensus is buy.
Does Rallies show live market data for ADIL?: Rallies combines live market context with ticker research for ADIL, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.